These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 15776202)

  • 1. Valacyclovir for the management of herpes viral infections.
    Chakrabarty A; Anderson NJ; Beutner R; Tyring SK
    Skin Therapy Lett; 2005 Feb; 10(1):1-4. PubMed ID: 15776202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valacyclovir for the treatment of genital herpes.
    Brantley JS; Hicks L; Sra K; Tyring SK
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):367-76. PubMed ID: 16771614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valacyclovir: approved and off-label uses for the treatment of herpes virus infections in immunocompetent and immunocompromised adults.
    Vigil KJ; Chemaly RF
    Expert Opin Pharmacother; 2010 Aug; 11(11):1901-13. PubMed ID: 20536295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV.
    Warren T; Harris J; Brennan CA
    Clin Infect Dis; 2004 Nov; 39 Suppl 5():S258-66. PubMed ID: 15494897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.
    Tyring SK; Baker D; Snowden W
    J Infect Dis; 2002 Oct; 186 Suppl 1():S40-6. PubMed ID: 12353186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster.
    Smiley ML; Murray A; de Miranda P
    Adv Exp Med Biol; 1996; 394():33-9. PubMed ID: 8815698
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of orally administered valacyclovir in experimentally EHV1-infected ponies.
    Garré B; Gryspeerdt A; Croubels S; De Backer P; Nauwynck H
    Vet Microbiol; 2009 Mar; 135(3-4):214-21. PubMed ID: 18986780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valacyclovir.
    Med Lett Drugs Ther; 1996 Jan; 38(965):3-4. PubMed ID: 8551979
    [No Abstract]   [Full Text] [Related]  

  • 9. Valacyclovir. New indication: for genital herpes, simpler administration.
    Can Fam Physician; 1999 Jul; 45():1698-700, 1703-5. PubMed ID: 10424269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of new antiherpes agents: famciclovir and valacyclovir.
    Stein GE
    J Am Pharm Assoc (Wash); 1997; NS37(2):157-63. PubMed ID: 9069689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valacyclovir.
    Acosta EP; Fletcher CV
    Ann Pharmacother; 1997 Feb; 31(2):185-91. PubMed ID: 9034421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.
    Gupta R; Wald A; Krantz E; Selke S; Warren T; Vargas-Cortes M; Miller G; Corey L
    J Infect Dis; 2004 Oct; 190(8):1374-81. PubMed ID: 15378428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age.
    Kimberlin DW; Jacobs RF; Weller S; van der Walt JS; Heitman CK; Man CY; Bradley JS
    Clin Infect Dis; 2010 Jan; 50(2):221-8. PubMed ID: 20014952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Valacyclovir].
    Biernat-Sudolska M
    Przegl Lek; 1998; 55(11):596-8. PubMed ID: 10216374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.
    Fife KH; Warren TJ; Justus SE; Heitman CK;
    Sex Transm Dis; 2008 Jul; 35(7):668-73. PubMed ID: 18461016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects.
    DeJesus E; Wald A; Warren T; Schacker TW; Trottier S; Shahmanesh M; Hill JL; Brennan CA;
    J Infect Dis; 2003 Oct; 188(7):1009-16. PubMed ID: 14513421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
    Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
    Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation.
    Fiddian P; Sabin CA; Griffiths PD
    J Infect Dis; 2002 Oct; 186 Suppl 1():S110-5. PubMed ID: 12353195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of valacyclovir in cats infected with feline herpesvirus 1.
    Nasisse MP; Dorman DC; Jamison KC; Weigler BJ; Hawkins EC; Stevens JB
    Am J Vet Res; 1997 Oct; 58(10):1141-4. PubMed ID: 9328668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: a pilot study.
    Miserocchi E; Modorati G; Galli L; Rama P
    Am J Ophthalmol; 2007 Oct; 144(4):547-51. PubMed ID: 17692271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.